AstraZeneca: Hold — Solid Q1 and Oncology Momentum, but Technical Headwinds Keep Upside Capped
AstraZeneca delivered a strong Q1 with $15.29B revenue (up 13% YoY) and continued oncology-led growth, but stretched valuation metrics, near-term technical weakness and execution risk on late-stage assets make the stock a Hold. We lay out a neutral trade plan for mid-term traders: entry at $182.58, target $195.00, stop $172.00 (45 trading days).